Sanofi

Documents

Financial606 concepts · 6,284 facts · Dec 2015 to Jun 2026

• Total48 · Dec 2015 to Dec 2025
• Non-current liabilities related to business combinations and to non-controlling interests38 · Dec 2015 to Jun 2026
• Current provisions and other current liabilities37 · Dec 2015 to Jun 2026
• Inventories37 · Dec 2015 to Jun 2026
• Deferred tax assets36 · Dec 2015 to Jun 2026
• Noncontrolling interests36 · Dec 2015 to Jun 2026
• Other intangible assets35 · Dec 2015 to Dec 2025
• Number of shares (in shares)34 · Dec 2015 to Jun 2026
• % of share capital for the period34 · Dec 2015 to Jun 2026
• Cash and cash equivalents33 · Dec 2015 to Jun 2026
• Equity33 · Dec 2015 to Jun 2026
• Noncurrent provisions (IFRS)33 · Dec 2015 to Jun 2026
• Assets (IFRS)32 · Dec 2015 to Jun 2026
• Borrowings32 · Dec 2015 to Jun 2026
• Contingent liabilities recognised in business combination32 · Dec 2015 to Jun 2026
• Current borrowings and current portion of noncurrent borrowings (IFRS)32 · Dec 2015 to Jun 2026
• Current liabilities related to business combinations and to non-controlling interests32 · Dec 2015 to Jun 2026
• Current trade receivables32 · Dec 2015 to Jun 2026
• Deferred tax liabilities (IFRS)32 · Dec 2015 to Jun 2026
• Derecognized receivables32 · Dec 2015 to Jun 2026
• Equity and liabilities32 · Dec 2015 to Jun 2026
• Equity attributable to owners of parent (IFRS)32 · Dec 2015 to Jun 2026
• Goodwill (IFRS)32 · Dec 2015 to Jun 2026
• Gross value of overdue receivables32 · Dec 2015 to Jun 2026

Segment69 concepts · 2,052 facts · Dec 2015 to Jun 2026

• Revenue from sale of goods (IFRS)1,326 · Dec 2015 to Dec 2025
• Revenue from Sale of Goods145 · Dec 2024 to Dec 2025
• Cost of Revenue45 · Dec 2019 to Jun 2026
• R&D Expense45 · Dec 2019 to Jun 2026
• Additions other than through business combinations property plant and equipment38 · Dec 2015 to Dec 2025
• Pharmaceuticals33 · Dec 2015 to Dec 2025
• Cost of sales29 · Dec 2018 to Dec 2025
• Other revenue (IFRS)29 · Dec 2018 to Dec 2025
• Profit loss attributable to noncontrolling interests29 · Dec 2018 to Dec 2025
• Research and development expense (IFRS)29 · Dec 2018 to Dec 2025
• Selling general and administrative expense (IFRS)29 · Dec 2018 to Dec 2025
• Share of profit loss of associates and joint ventures accounted for using equity method29 · Dec 2018 to Dec 2025
• Purchase of intangible assets classified as investing activities23 · Dec 2018 to Dec 2025
• Purchase of property plant and equipment classified as investing activities23 · Dec 2018 to Dec 2025
• Goodwill20 · Dec 2017 to Dec 2023
• Intangible Assets (excluding Goodwill)12 · Dec 2024 to Dec 2025
• Property, Plant & Equipment, Net12 · Dec 2024 to Dec 2025
• SG&A Expense12 · Jun 2024 to Jun 2026
• Other Revenue11 · Dec 2024 to Jun 2026
• Net Income Attributable to Noncontrolling Interests9 · Jun 2024 to Jun 2026
• États-Unis6 · Jun 2020 to Jun 2026
• Share of Profit of Associates and Joint Ventures6 · Dec 2024 to Dec 2025
• Capital Expenditures5 · Jun 2024 to Jun 2026
• Biopharma (operating segment)4 · Dec 2022 to Dec 2025

IFRS295 concepts · 1,348 facts · Dec 2019 to Jun 2026

• Intangible Assets (excluding Goodwill)48 · Dec 2019 to Dec 2025
• Cash and Equivalents45 · Dec 2019 to Dec 2025
• Property, Plant & Equipment, Net38 · Dec 2019 to Dec 2025
• Stockholders Equity38 · Dec 2019 to Dec 2025
• Total Borrowings33 · Dec 2024 to Dec 2025
• Net Income30 · Dec 2019 to Jun 2026
• Other Comprehensive Income28 · Dec 2019 to Dec 2025
• Total Comprehensive Income28 · Dec 2019 to Dec 2025
• Equity Change: Exercise of Options26 · Dec 2019 to Dec 2025
• Other Intangible Assets (IFRS Line Item)25 · May 2024 to Dec 2025
• Dividends Recognised as Distributions to Owners of Parent24 · Dec 2019 to Dec 2025
• Equity Change: Purchase of Treasury Shares24 · Dec 2019 to Dec 2025
• Dividends Recognised as Distributions to Noncontrolling Interests22 · Dec 2019 to Dec 2025
• Equity Change: Ownership Changes Without Loss of Control22 · Dec 2019 to Dec 2025
• Bank Overdrafts (Cash Equivalents)18 · Dec 2024 to Dec 2025
• Reduction of Issued Capital18 · Dec 2024 to Dec 2025
• Miscellaneous Other Operating Expense16 · Dec 2019 to Dec 2025
• Noncurrent Provisions12 · Dec 2024 to Dec 2025
• R&D Expense11 · Dec 2019 to Jun 2026
• Total Lease Liabilities11 · Jun 2021 to Dec 2025
• Investments in Joint Ventures10 · Dec 2024 to Dec 2025
• Miscellaneous Other Operating Income10 · Dec 2019 to Dec 2025
• Other Financing Cash Flows10 · Dec 2024 to Dec 2025
• Accounts Receivable, Net9 · Dec 2019 to Dec 2025

Geography16 concepts · 516 facts · Dec 2015 to Jun 2026

• Property, Plant & Equipment, Net119 · Dec 2016 to Jun 2026
• Revenue from sale of goods (IFRS)96 · Dec 2015 to Dec 2025
• Intangible Assets (excluding Goodwill)75 · Dec 2016 to Jun 2026
• France48 · Dec 2015 to Dec 2025
• Actuarial gains losses arising from changes in financial assumptions net defined benefit liability asset44 · Dec 2015 to Dec 2025
• Gain loss on remeasurement of net defined benefit liability asset44 · Dec 2015 to Dec 2025
• Actuarial gains losses arising from changes in demographic assumptions net defined benefit liability asset41 · Dec 2015 to Dec 2025
• Weighted average duration of defined benefit obligation16 · Dec 2015 to Dec 2018
• United States10 · Dec 2017 to Dec 2025
• UK9 · Dec 2017 to Dec 2025
• Goodwill5 · Jun 2019 to Jun 2025
• Payments for premiums and claims annuities and other policy benefits3 · Dec 2015 to Dec 2017
• Net foreign exchange loss2 · Dec 2016 to Dec 2018
• Termination benefit payments2 · Dec 2018
• Clariant retained liabilities - specially chemicals business1 · Dec 2017
• Percentage of entitys revenue1 · Dec 2022

Product5 concepts · 12 facts · Dec 2020 to Dec 2025

• Proceeds from disposals of property plant and equipment intangible assets other than goodwill investment property and other noncurrent assets6 · Dec 2020 to Dec 2024
• ELOCTATE2 · Dec 2022
• Other intangible assets2 · Dec 2024 to Dec 2025
• Impairment loss recognised in profit or loss intangible assets other than goodwill1 · Dec 2022
• Reversal of impairment loss recognised in profit or loss intangible assets other than goodwill1 · Dec 2022

Guidance1 concepts · 2 facts · Oct 2021

• EPS (Diluted) Growth Guidance2 · Oct 2021

Segments19 members · 1,823 facts

• Pharmaceuticals602 · Dec 2015 to Dec 2022
• Biopharma541 · Dec 2021 to Dec 2025
• Consumer Healthcare263 · Dec 2015 to Dec 2023
• Vaccines140 · Dec 2015 to Dec 2022
• Biopharma segment75 · Jun 2022 to Jun 2026
• All Other Segments64 · Dec 2018 to Dec 2025
• All other segments37 · Jun 2020 to Jun 2026
• Reportable segments28 · Dec 2019 to Dec 2025
• Consumer healthcare segment15 · Dec 2017 to Dec 2023
• Opella12 · Dec 2023 to Dec 2024
• Animal Health Business10 · Dec 2015 to Dec 2018
• Pharmaceuticals6 · Dec 2017 to Dec 2022
• Pharmaceuticals segment6 · Jun 2020 to Jun 2022
• Vaccines6 · Dec 2017 to Dec 2022
• Vaccines segment6 · Jun 2020 to Jun 2022
• Opella Business5 · Dec 2021 to Dec 2025
• Opella4 · Jun 2023 to Jun 2024
• Libtayo2 · Dec 2022
• OPALJV Co1 · Dec 2025

Geographical areasifrs-full:GeographicalAreasAxis29 members · 516 facts

• US69 · Dec 2015 to Dec 2025
• FR66 · Dec 2015 to Dec 2025
• GB56 · Dec 2015 to Dec 2025
• DE46 · Dec 2015 to Dec 2025
• Us35 · Dec 2016 to Jun 2026
• Other countries30 · Dec 2016 to Dec 2025
• Fr25 · Dec 2016 to Jun 2026
• Other countries excluding europe and north america22 · Jun 2021 to Jun 2026
• Europe18 · Dec 2016 to Dec 2025
• Reportable geographical zones17 · Jun 2019 to Jun 2025
• Europe16 · Dec 2015 to Dec 2025
• North america14 · Dec 2016 to Dec 2023
• Europe112 · Dec 2018 to Dec 2020
• North america112 · Dec 2018 to Dec 2020
• North America11 · Dec 2015 to Dec 2023
• Other Countries11 · Dec 2015 to Dec 2025
• Reportable Geographical Zones11 · Dec 2015 to Dec 2025
• Europe8 · Dec 2024 to Jun 2026
• Cn6 · Dec 2024 to Jun 2026
• Other Countries In Segment Results6 · Dec 2018 to Dec 2023
• Europe15 · Dec 2017 to Dec 2020
• North America14 · Dec 2017 to Dec 2020
• RU4 · Dec 2020 to Dec 2022
• CN3 · Dec 2023 to Dec 2025
• Other Countries Excluding Europe And North America3 · Dec 2021 to Dec 2023
• Other Countries In Segement Results3 · Dec 2017 to Dec 2019
• AR1 · Dec 2018
• Germany1 · Dec 2017
• VE1 · Dec 2016

Components of equity9 members · 229 facts

• Equity attributable to owners of parent37 · Dec 2019 to Dec 2025
• Retained earnings32 · Dec 2019 to Dec 2025
• Noncontrolling interests31 · Dec 2019 to Dec 2025
• Accumulated other comprehensive income28 · Dec 2019 to Dec 2025
• Treasury shares25 · Dec 2019 to Dec 2025
• Additional paidin capital24 · Dec 2019 to Dec 2025
• Issued capital24 · Dec 2019 to Dec 2025
• Reserve of sharebased payments22 · Dec 2019 to Dec 2025
• Reserve of exchange differences on translation6 · Dec 2024 to Dec 2025

Geographical areasifrs-full:GeographicalAreasAxis7 members · 132 facts

• Us38 · Dec 2024 to Dec 2025
• Europe38 · Dec 2024 to Dec 2025
• Other countries in segment results32 · Dec 2024 to Dec 2025
• Cn6 · Dec 2024 to Dec 2025
• Fr6 · Dec 2024 to Dec 2025
• Other countries6 · Dec 2024 to Dec 2025
• Reportable geographical zones6 · Dec 2024 to Dec 2025

Carrying amount accumulated depreciation amortisation and impairment and gross carrying amount4 members · 68 facts

• Gross carrying amount34 · Dec 2024 to Dec 2025
• Accumulated depreciation amortisation and impairment30 · Dec 2024 to Dec 2025
• Allowance for credit losses2 · Dec 2024 to Dec 2025
• Write down2 · Dec 2024 to Dec 2025

Business line pharmacy and geography3 members · 54 facts

• États-Unis19 · Jun 2020 to Jun 2026
• Europe18 · Jun 2020 to Jun 2026
• Autres pays17 · Jun 2020

Maturity8 members · 51 facts

• Not later than one year10 · Dec 2024 to Dec 2025
• Later than five years9 · Dec 2024 to Dec 2025
• Later than four years and not later than five years7 · Dec 2024 to Dec 2025
• Later than one year and not later than two years7 · Dec 2024 to Dec 2025
• Later than three years and not later than four years7 · Dec 2024 to Dec 2025
• Later than two years and not later than three years7 · Dec 2024 to Dec 2025
• Later than one year and not later than three years2 · Dec 2024 to Dec 2025
• Later than three years and not later than five years2 · Dec 2024 to Dec 2025

Classes of assets8 members · 38 facts

• Longterm borrowings10 · Dec 2024 to Dec 2025
• Increase decrease interest rate and currency derivatives used to manage debt10 · Dec 2024 to Dec 2025
• Short term debt and current portion of long term debt10 · Dec 2024 to Dec 2025
• Current assets2 · Dec 2024 to Dec 2025
• Non current assets2 · Dec 2024 to Dec 2025
• Securities quoted in an active market2 · Dec 2019
• Commercial paper program in usa1 · Dec 2025
• Contingent consideration relating to divestments1 · Dec 2020

Hedging instruments9 members · 37 facts

• Currency derivatives financial6 · Dec 2025
• Currency derivatives6 · Dec 2025
• Currency derivatives operating6 · Dec 2025
• Equity derivatives6 · Dec 2025
• Interest rate derivatives6 · Dec 2025
• Cross currency swap3 · Dec 2025
• Forward currency sales in usdollar2 · Dec 2025
• Forward currency purchased in usdollar usbond1 · Dec 2025
• Forward currency purchases in usdollar usbond1 · Dec 2025

Classes of intangible assets other than goodwill18 members · 34 facts

• Computer software2 · Dec 2024 to Dec 2025
• Acquired rd2 · Dec 2024 to Dec 2025
• Marketed products2 · Dec 2024 to Dec 2025
• Marketed products trademarks and other rights2 · Dec 2024 to Dec 2025
• Principal marketed products ablynx2 · Dec 2024 to Dec 2025
• Principal marketed products ayvakit2 · Dec 2024 to Dec 2025
• Principal marketed products beyfortus2 · Dec 2024 to Dec 2025
• Principal marketed products bioverativ2 · Dec 2024 to Dec 2025
• Principal marketed products boehringeringelheim consumer healthcare2 · Dec 2024 to Dec 2025
• Principal marketed products chattem2 · Dec 2024 to Dec 2025
• Principal marketed products protein sciences2 · Dec 2024 to Dec 2025
• Principal marketed products qunol2 · Dec 2024 to Dec 2025
• Principal marketed products rezurock2 · Dec 2024 to Dec 2025
• Principal marketed products tzield2 · Dec 2024 to Dec 2025
• Principal marketed products wayrilz2 · Dec 2024 to Dec 2025
• Technological platforms2 · Dec 2024 to Dec 2025
• Principal marketed products aventis1 · Dec 2024
• Principal marketed products genzyme1 · Dec 2024

Measurement6 members · 31 facts

• Value on redemption10 · Dec 2024 to Dec 2025
• Value on redemption after derivative instruments8 · Dec 2024 to Dec 2025
• Adjustment to debt measured at fair value4 · Dec 2025
• Amortized cost4 · Dec 2025
• Value on redemption before derivative instruments3 · Dec 2025
• At market value2 · Dec 2024 to Dec 2025

Significant investments in subsidiaries6 members · 19 facts

• Opella business11 · Dec 2024 to Dec 2025
• Others4 · Dec 2024 to Dec 2025
• Ablynx1 · Dec 2025
• Bioverativ1 · Dec 2025
• Blueprint medicines netherlands b.v.1 · Dec 2025
• Principia biopharma inc1 · Dec 2025

Business activity1 member · 15 facts

• Biopharma15 · Jun 2025 to Jun 2026

Defined benefit plans1 member · 14 facts

• Pensions and other post employment benefits14 · Dec 2024 to Dec 2025

Significant investments in associates6 members · 14 facts

• Regeneron4 · Dec 2024 to Dec 2025
• Opaljvco3 · Dec 2024 to Dec 2025
• Aggregated individually immaterial associates2 · Dec 2024 to Dec 2025
• Associates2 · Dec 2024 to Dec 2025
• Euroapi2 · Dec 2024 to Dec 2025
• Regeneron pharmaceuticals inc1 · Dec 2024

Geography3 members · 13 facts

• Vaccines7 · Jun 2021
• Consumer Healthcare4 · Jun 2021
• Reste du Monde2 · Jun 2020 to Jun 2026

Operating segment1 member · 11 facts

• Autres11 · Jun 2020 to Jun 2026

Business combinations7 members · 10 facts

• Blueprint medicines corporation2 · Dec 2025
• Opella business2 · Dec 2024 to Dec 2025
• Opella business2 · Dec 2024 to Dec 2025
• Provention bio inc1 · Dec 2024
• Qribintermediate holdings llc1 · Dec 2024
• Vicebio ltd1 · Dec 2025
• Vigil neurosciences1 · Dec 2025

Classes of property plant and equipment5 members · 10 facts

• Buildings2 · Dec 2024 to Dec 2025
• Fixtures and fittings2 · Dec 2024 to Dec 2025
• Land2 · Dec 2024 to Dec 2025
• Machinery and equipment12 · Dec 2024 to Dec 2025
• Property plant and equipment in process2 · Dec 2024 to Dec 2025

Classes of provisions4 members · 10 facts

• Provisions for pensions and other post employment benefits4 · Dec 2024 to Dec 2025
• Miscellaneous other provisions2 · Dec 2024 to Dec 2025
• Non current restructuring provision2 · Dec 2024 to Dec 2025
• Provisions for other long term benefits2 · Dec 2024 to Dec 2025

Expense categories1 member · 10 facts

• Amortization of computer software and other rights of an industrial or operational nature10 · Dec 2024 to Dec 2025

Product or service8 members · 10 facts

• Eloctate2 · Dec 2022
• Pharmaceuticals2 · Dec 2020 to Dec 2021
• ALTUVIIIO1 · Dec 2022
• Biopharma1 · Dec 2024
• Consumer Healthcare1 · Dec 2021
• Enjaymo Global Rights1 · Dec 2024
• Seprafilm1 · Dec 2020
• Tolebrutinib1 · Dec 2025

Classes of liabilities2 members · 8 facts

• Current liabilities4 · Dec 2024 to Dec 2025
• Non current liabilities4 · Dec 2024 to Dec 2025

Counterparties3 members · 8 facts

• Swedish orphan biovitrum ab4 · Dec 2025
• Regeneron pharmaceuticals inc3 · Dec 2024 to Dec 2025
• Astra zeneca1 · Dec 2025

Joint ventures4 members · 8 facts

• Aggregated individually immaterial associates2 · Dec 2024 to Dec 2025
• Joint ventures2 · Dec 2024 to Dec 2025
• Infraserv gmbh and co hochst kg2 · Dec 2024 to Dec 2025
• Mspvaccine company2 · Dec 2024 to Dec 2025

Segment consolidation items1 member · 6 facts

• Material reconciling items6 · Dec 2024 to Dec 2025

Income statement location13 members · 6 facts

• Commercialization related expenses2 · Dec 2024 to Dec 2025
• Share of profit or loss from commercialization of monoclonal antibodies2 · Dec 2024 to Dec 2025
• Share of profit or loss from commercialization of zaltrap2 · Dec 2024 to Dec 2025

Geography and product1 member · 4 facts

• Pharmaceuticals4 · Jun 2021

Categories of related parties1 member · 4 facts

• Other related parties4 · Dec 2024 to Dec 2025

Classes of financial assets2 members · 4 facts

• Cash flow and fair value hedge2 · Dec 2024 to Dec 2025
• Foreign currency translation2 · Dec 2024 to Dec 2025

Products and servicesifrs-full:ProductsAndServicesAxis4 members · 4 facts

• Enjaymo global rights1 · Dec 2025
• Enjaymo global rights1 · Dec 2024
• Pharmaceuticals1 · Dec 2020
• Seprafilm1 · Dec 2020

Temporary difference unused tax losses and unused tax credits2 members · 4 facts

• Deferred tax relating to capitalisation of rdexpenses2 · Dec 2024 to Dec 2025
• Deferred tax relating to restructuring provisions2 · Dec 2024 to Dec 2025

Assets acquisition2 members · 3 facts

• Assets acquisition2 · May 2024 to Dec 2025
• Blueprint medicines corporation1 · Dec 2025

Classes of intangible assets and goodwill1 member · 2 facts

• Goodwill2 · Dec 2024 to Dec 2025

Net defined benefit liability asset1 member · 2 facts

• Uncertainties over income tax treatments2 · Dec 2024 to Dec 2025

Products and servicesifrs-full:ProductsAndServicesAxis2 members · 2 facts

• Eloctate1 · Dec 2022
• Enjaymo Global Rights1 · Dec 2024

Counterparty name1 member · 2 facts

• Antibodies alliance2 · Dec 2024 to Dec 2025

Nonadjusting events after reporting period1 member · 1 facts

• Major collaboration agreement1 · Nov 2024